knowledge -WSS

knowledge

author：entertainment 2025-09-06 02:06:00 - browse：9

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： STAT Readout Newsletter: Biotech news today

WSS

Undocumented workers face uncertainty as immigration law takes effect in Florida

Fatty liver disease was alleviated by Lilly’s ‘triple

Prescription digital therapeutics are key to pharma’s future

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Undocumented workers face uncertainty as immigration law takes effect in Florida

Why a market frenzy over new weight loss drugs defies logic

hotspot

knowledge

Wikipedia

Duchenne breakthrough therapy leaves behind pioneering families

Smaller biotechs seek to piggyback on weight loss drug boom

Activists slam private health insurers over coverage restrictions

FDA clears Verve to begin U.S. study of gene

Trump demands the U.S. pay no more for drugs than other countries … again

Roivant's CEO is a star, but biotech's black hole persists

New air purifier tech could be key to improving indoor air quality

Health tech investors get more selective as pandemic boom fades

In Memoriam: Notable people who died in 2023

Roivant's CEO is a star, but biotech's black hole persists

focus

Roche acquires Telavant from Roivant, adding experimental IBD treatment

What affirmative action's end means to a medical student

AstraZeneca lung cancer study comes in below expectations

Being 'nonadherent' patient made me a more empathetic doctor

Beware reading your test results before your doctor does

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Wikipedia

focus

Wikipedia

leisure time